William Blair Starts LogicBio Therapeutics (LOGC) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Chardan Capital Markets Starts LogicBio Therapeutics (LOGC) at Buy
November 13, 2018 6:47 AM ESTChardan Capital Markets analyst Gbola Amusa initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Buy rating and a price target of $20.00.
The analyst comments "LogicBios pipeline reflects a focus on indications that play to its strengths. The advantage lies in indications where 1)... More
Barclays Starts LogicBio Therapeutics (LOGC) at Overweight
November 13, 2018 4:16 AM ESTBarclays analyst Gena Wang initiates coverage on LogicBio Therapeutics (NASDAQ: LOGC) with a Overweight rating and a price target of $24.00.
For an analyst ratings summary and ratings history on LogicBio Therapeutics click here. For more ratings news on LogicBio Therapeutics click here.
Shares of LogicBio Therapeutics closed at $13.72 yesterday.
... More